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Dr Robert C. Gorman (Philadelphia, Pa). This is an interesting
and potentially important study because you are trying to assess
how mechanical events in the heart that occur after an infarct affect
the biology of the remaining normally perfused myocardium.
As surgeons, we have focused primarily on influencing those
geometric properties with our surgical treatments for heart failure,
with the tacit assumption that the remaining myocardium is inher-
ently normal. This line of work is very important because it may
help to explain why our results for surgical heart failure are not as
good as we would expect after we return the heart to normal geom-
etry, being that the existing myocardium has some inherent changes
in it that have altered it beyond surgical repair.
That being said, I have 2 questions in regard to the technical
performance of your study and then one theoretical question with
regard to the therapeutic implications for your study.
You presented your sonomicrometry data that demonstrated the
regional contractile function, and I am a little concerned that the con-
tractile function within the infarct itself still showed contractile
properties. In our long experience with sonomicrometry in this
model, typically we see a very dyskinetic effect within the infarcts
demonstrating a lot of infarct expansion. You did not show that,
so I would be interested in your explaining that to us.
Second, when you are measuring cytochrome c, are you trying to
measure cytosolic cytochrome c?
Dr Yankey. Yes, sir.
Dr Gorman. I am a little concerned about your normal tissue,
which shows a tremendous amount of cytosolic cytochrome c,
which we would not expect to see. That is a typical problem with
trying to measure that property. You have to degrade the myocar-
dium, and you wind up banging up the mitochrondia and gettomg
cytochrome c all over the place. It is an important end point, but
we found it difficult to measure.
Dr Yankey. With regard to the first question pertaining to the
fractional contraction of the infarct region, we looked at about 8
sheep and we took an average of the various fractional contraction
values. When we looked at it over an 8-week period, it was a positive
value that indicates dysfunctional dilatation of the heart.acic and Cardiovascular Surgery c Volume 135, Number 5 997
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CSPSome of the sonomicrometric data that we looked at did have a few
values showing the dilatation, but we evaluated only an 8-week pe-
riod. I believe that if we had looked longer than that, we would have
seen much greater positive values of the fractional contraction.
Pertaining to cytosolic cytochrome c, I do understand the prob-
lem you are addressing, but it was very difficult to actually get the
normal value. We just did the best that we could. That is the main
reason why we chose to also look at the mitochondrial Bax and
then show the values for caspase 3 and PARP as well. I do under-
stand, but that was the best that we could do to show that.
Dr Gorman. I want to expand on my question. The issue is that
you showed how stretch affects, potentially, apoptosis. Should we be
trying to treat mechanical stretch early with surgical means or should
we be looking for pharmacologic techniques for preventing apoptosis?998 The Journal of Thoracic and Cardiovascular Surgery c MaDrYankey. I think we should try to treat stretch in the earlier
phases, so that we can at least prevent the progressive apoptotic
cell loss in the adjacent regions and then the ongoing problem
in the remote areas as well. It is very important that we do in-
tervene as soon as possible so that we can prevent this apoptotic
cascade.
Dr Gorman. One other thing: When you do your correlation
analysis with your apoptosis and stretch, you really should not put
your infarct data in that. Apoptosis in the infarct, of which you
showed a tremendous amount, is not really the phenomenon we
are interested in. We are interested in apoptosis in the normally per-
fused regions. I am not sure that apoptosis in the infarct is not a good
thing. That may be associated with scar remodeling and things like
that. That is one thing to consider.y 2008
